After two rounds of review inquiries, Jun Cheng technology's restructuring failed, and the symbol company's financial irregularities have become the focus of regulatory attention. | Quick read announcement.
Jun Cheng Technology announced the abandonment of the planned assets restructuring that had been planned for over a year. This involved the acquisition of a controlling stake in the automotive instrument company New Times for 0.247 billion yuan; During the planning period, the company received two rounds of "Inquiry Letters for Review" issued by the Shenzhen Stock Exchange, and recently disclosed a revised report draft; The Shenzhen Stock Exchange has noticed that New Times has used borrowed funds for the family consumption of the actual controller, involving behaviors such as receiving, transferring, and misappropriating funds by others.
shenzhen transsion holdings co., ltd.: Currently in negotiations with patent holders on patent rights. Emerging markets are still in the trend of transitioning from feature phones to asia vets. | Earnings conference direct hit
① Zhu Zhaojiang stated that overall, the penetration rate of smart devices in emerging markets is lower compared to North America, Western Europe, and developed economies in the Asia-Pacific region and the china market. Replacing feature phones with smart devices remains an important factor driving smart device market growth in emerging markets; ② He mentioned that Transsion is currently negotiating with patent holders to promote the establishment of reasonable licensing fees within the framework of fairness, reasonableness, and non-discrimination principles.
Increase the proportion of high value-added products Henan Mingtai Al.Industrial plans to change some of the raised funds investment projects | Quick Read Announcement
① In the opportunity of the "Zhengkai 3 million autos industry belt," henan mingtai al.industrial is increasing investment in new energy battery materials and aluminum plates and strips for autos; ② The company has entered high-tech and high value-added fields such as aluminum for new energy, aluminum for new materials, aluminum for transportation, and aluminum for lightweight autos.
Private capital will be introduced in the new approved projects. China National Nuclear Power is still in a stage of rapid growth and development | Highlights from the earnings conference.
① The company will introduce private capital into the newly approved projects; ② "The company's asset scale has exceeded 600 billion yuan and is still in a stage of rapid growth."
Tasly Pharmaceutical Group: Some products are priced down, leading to a decrease in Q3 gross margin. All parties are actively promoting the trade with China Resources Sanjiu Medical & Pharmaceutical | Straight to the earnings conference
① Due to the overall low prosperity in the pharmaceutical commerce industry, the company's revenue in this sector declined in the third quarter of this year; although revenue in the pharmaceutical industry sector grew year-on-year, the price reduction of some products led to a decrease in gross margin, and the company expects that the gross margin may remain stable in the future. ② Regarding the equity trade matter of the company's major shareholder with china resources sanjiu medical & pharmaceutical, the company's general manager Cai Jinyong stated that the company and relevant parties are actively promoting the various aspects of this trade.
Clinical results did not meet expectations. Tasly Pharmaceutical Group suspends the eight-year development "marathon" of the new anti-cancer drug | Summary of the announcement.
① Tasly Pharmaceutical Group announced the suspension of the research and development of its anmeimu monoclonal antibody. Since its approval in 2016, the drug has reached the IIb phase of clinical research; ② According to the clinical research results, the efficacy of anmeimu monoclonal antibody did not meet expectations, and other EGFR monoclonal antibody biosimilar drugs face fierce competition; ③ This project also involves Sino Biopharmaceutical's equity participation, with Tasly Pharmaceutical Group and Sino Biopharmaceutical respectively recognizing an impairment loss of 0.162 billion yuan and 14.1448 million yuan in assets.